甲状腺乳头状癌鞋钉亚型:单中心大样本系列的临床/分子特征及与传统组织学类型的比较
前瞻性研究比较25例甲状腺乳头状癌鞋钉亚型(HPTC)与165例连续传统乳头状癌(PTC)患者的临床和分子特征,所有患者均行甲状腺全切和放射性碘治疗。HPTC表现为更大肿瘤、更多淋巴结转移和远处转移、更高TP53突变率及更差预后,随访中32%存在生化/结构性疾病。
要点
- HPTC患者肿瘤更大、淋巴结转移和远处转移更常见,预后更差。
- HPTC中BRAFV600E突变率与传统PTC相似,但TP53突变率更高。
- 肿瘤大小是HPTC持续性疾病与极好缓解之间的唯一显著差异。
核心结论
- HPTC是一种侵袭性变异型,以肿瘤大、淋巴结受累、倾向转移和预后更差为特征。
研究设计与样本
- 前瞻性研究,2010年至2016年纳入25例HPTC患者和165例连续传统PTC患者,进行临床和分子(BRAF、RAS、TERT启动子、TP53突变)比较,所有患者接受甲状腺全切和放射性碘治疗,19例HPTC患者有随访数据。
主要发现
- HPTC患者中64%鞋钉成分≥30%,64%为多灶性疾病,平均肿瘤大小30 mm,96%有血管侵犯,68%为N1,12%为M1。
- HPTC中58%存在BRAFV600E突变,12%有TERT启动子突变,17%有TP53突变,无RAS突变。
- 平均随访39个月,32%的患者存在生化 and/or 结构性疾病;持续性疾病患者与极好缓解患者肿瘤大小分别为40 mm和24 mm(p=0.02)。
- 与PTC对照组相比,HPTC患者肿瘤更大(30 mm vs. 16 mm;p<0.001),淋巴结受累更频繁(68% vs. 38%;p=0.01),远处转移更多(16% vs. 3%;p<0.0001),BRAFV600E突变患病率相似(58% vs. 59%),TP53突变患病率更高(17% vs. 1%;p<0.05),结局更差(结构/生化疾病:32% vs. 9%;p<0.0001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The hobnail variant of papillary thyroid carcinoma (HPTC) has an aggressive behavior. The aims of this prospective study were to define the clinical/molecular characteristics of HPTC, and to compare them to those of conventional papillary thyroid carcinoma (PTC). METHODS: From 2010 to 2016, 25 cases of HPTC, characterized clinically and molecularly (BRAF, RAS, TERT promoter, and TP53 mutations), were compared to a series of 165 consecutive cases of PTC. All patients underwent total thyroidectomy and received radioactive iodine treatment. Follow-up was available for 19 HPTC patients. RESULTS: Among the HPTC patients, 64% had a hobnail component ≥30%, and 64% had multifocal disease. The mean tumor size was 30 mm; 96% of tumors were angio-invasive; 68% were N1, and 12% were M1; 58% harbored the BRAFV600E mutation, 12% had a mutation in the TERT promoter, 17% had a TP53 mutation, and not had a RAS mutation. At a mean follow-up of 39 months, 32% of patients had biochemical and/or structural disease. Tumor size was the only significant difference between patients with persistent disease and those with an excellent response (40 mm and 24 mm, respectively; p = 0.02). Compared to the PTC control group, the HPTC patients had larger tumors (30 mm vs. 16 mm; p < 0.001), more frequent lymph node involvement (68% vs. 38%; p = 0.01), and remote disease (16% vs. 3%; p < 0.0001), a similar prevalence of the BRAFV600E mutation (58% vs. 59%), a higher prevalence of TP53 mutations (17% vs. 1%; p < 0.05), and a worse outcome (structural/biochemical disease: 32% vs. 9%; p < 0.0001). CONCLUSIONS: HPTC is an aggressive variant, characterized by large tumor size, lymph node involvement, a tendency to metastasize, and a worse outcome.
引用
- Watutantrige-Fernando S, Vianello F, Barollo S, et al. The Hobnail Variant of Papillary Thyroid Carcinoma: Clinical/Molecular Characteristics of a Large Monocentric Series and Comparison with Conventional Histotypes. Thyroid. 2018. PMID: 29179638. doi:10.1089/thy.2017.0248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。